Lisa Roberts, patient of Dr. Whitnee Brown, DNP, CRNP, PMHNP, FNP, on her computer working from home.

Lisa Roberts has raised a family, reached an impressively high level in her career, and was an anchor for her mother and other family members. When, within a very short period of time, her brother and son were diagnosed with chronic illness, and her mother passed away after a too-brief illness, Lisa was unmoored. She found herself wondering why she was not grieving, why she was not feeling much at all. She did not enjoy her job or even get out of bed in the morning,

“My problems were not going away, and I found myself wishing I could just not be here,” said Ms. Roberts.

She made an appointment to see Whitnee Brown, a psychiatric nurse practitioner and Doctor of Nursing Practice in nearby Birmingham, Alabama. Dr. Brown worked with Lisa on exercises that could help Lisa accept her grief, and they did help. Yet they both acknowledged that Lisa needed more. They agreed to try a medication treatment plan. Dr. Brown offers the GeneSight® test in her practice and ordered the test for Lisa. The GeneSight test analyzes how a patient’s genes may affect their outcomes to certain mental health medications, providing insight on which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on their genetics. Lisa Roberts, patient of Dr. Whitnee Brown, DNP, CRNP, PMHNP, FNP, driving on the highway.

“I did not have time for a lengthy trial-and-error process for medication; I needed relief,” said Ms. Roberts, “so I was happy to learn about the GeneSight test.”

Dr. Brown used Lisa’s GeneSight test results to aid in prescribing a medication, and today she is on a medication that works for her.

“I’m here!” exclaimed Lisa. “I am able to help my family members, taking them to appointments, go to my job—in fact, I was just promoted–without wanting to just run away!”

Lisa Roberts, a patient of Dr. Whitnee Brown DNP, CRNP, PMHNP, FNP, takes her prescribed medication.

Dr. Brown and Ms. Roberts shared their experiences in a multi-media news release to support the most recent GeneSight Mental Health Monitor survey, which examined Americans’ attitudes towards mental health medications like antidepressants.

GeneSight Mental Health Monitor Results

Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) of those who have never been on a mental health medication from taking them.

The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns.

Among those diagnosed with depression and/or anxiety, 62% of patients whose healthcare provider did not use PGx testing wish they had been informed about it.

The GeneSight Mental Health Monitor also revealed:

  • 67% of Americans surveyed strongly agree that it is socially acceptable to take medications for mental health
  • 62% of Americans surveyed strongly agree that they would feel comfortable discussing their use of mental health medications with their family
  • 66% of Americans surveyed have a positive view of other people taking mental health medications, with just 5% reporting a negative view.

In fact, respondents rated the effectiveness of mental health medications as similar to that of medications prescribed for their high blood pressure (94%), high cholesterol (90%), and arthritis (84%).

About the GeneSight Mental Health Monitor

The GeneSight Mental Health Monitor is a nationwide survey conducted online by ACUPOLL Precision Research, Inc. between January 24 – February 10, 2025, among a representative sample (n=1089) of U.S. adults age 18+. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%. A nationally representative sample of adults aged 18 years or older was recruited and balanced to match U.S. Census quotas across five primary metrics (i.e., age, gender, income, region, ethnicity).

In addition to the nationally representative sample, a statistically reliable sample was desired of respondents who were self-reported as being diagnosed by a medical professional with depression or anxiety. The study also used mental health screening instruments, the Patient Health Questionnaire-2 (PHQ-2) for depression, and the General Anxiety Disorder (GAD-2) for anxiety, to better understand this population.

ACUPOLL has more than 30 years of experience conducting statistically valid research through careful recruiting and quality control measures.

Independently Reviewed 

This survey was independently reviewed on February 26, 2025, by Paul J. Lavrakas, Ph. D. and was found to be “an exceptionally high-quality nonprobability survey whose findings can be trusted with a good deal of confidence.” Lavrakas served the American Association for Public Opinion Research (AAPOR) as its first Conference Operations chair in 1996-1997, as Program Chair in 1997-1998, and as Senior Counselor at Large in 2008-2010. In 2003, he was the co-winner of the AAPOR Innovator’s award for helping to establish the Standard’s Definitions Manual. He was elected to serve AAPOR as its Vice President, President, and Past President from 2011-2014. In 2019, he was honored with AAPOR’s Exceptionally Distinguished Achievement lifetime award for his contributions to the field of survey research.

Our articles are for informational purposes only and are reviewed by our Medical Information team, which includes PharmDs, MDs, and PhDs. Do not make any changes to your current medications or dosing without consulting your healthcare provider.

The GeneSight test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications. As with all genetic tests, the GeneSight test results have limitations and do not constitute medical advice. The test results are designed to be just one part of a larger, complete patient assessment, which would include proper diagnosis and consideration of your medical history, other medications you may be taking, your family history, and other factors.

If you are a healthcare provider and interested in learning more about the GeneSight test, please contact us at 855.891.9415. If you are a patient, please talk with your doctor to see if the GeneSight test may be helpful.

Take the next step